These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 9357534

  • 1. Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure.
    Campiani G, Cappelli A, Nacci V, Anzini M, Vomero S, Hamon M, Cagnotto A, Fracasso C, Uboldi C, Caccia S, Consolo S, Mennini T.
    J Med Chem; 1997 Oct 24; 40(22):3670-8. PubMed ID: 9357534
    [Abstract] [Full Text] [Related]

  • 2. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
    Cappelli A, Anzini M, Vomero S, Canullo L, Mennuni L, Makovec F, Doucet E, Hamon M, Menziani MC, De Benedetti PG, Bruni G, Romeo MR, Giorgi G, Donati A.
    J Med Chem; 1999 May 06; 42(9):1556-75. PubMed ID: 10229626
    [Abstract] [Full Text] [Related]

  • 3. Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studies.
    Campiani G, Morelli E, Gemma S, Nacci V, Butini S, Hamon M, Novellino E, Greco G, Cagnotto A, Goegan M, Cervo L, Dalla Valle F, Fracasso C, Caccia S, Mennini T.
    J Med Chem; 1999 Oct 21; 42(21):4362-79. PubMed ID: 10543880
    [Abstract] [Full Text] [Related]

  • 4. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
    Cappelli A, Anzini M, Vomero S, Mennuni L, Makovec F, Doucet E, Hamon M, Bruni G, Romeo MR, Menziani MC, De Benedetti PG, Langer T.
    J Med Chem; 1998 Feb 26; 41(5):728-41. PubMed ID: 9513601
    [Abstract] [Full Text] [Related]

  • 5. Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characterization.
    Butini S, Budriesi R, Hamon M, Morelli E, Gemma S, Brindisi M, Borrelli G, Novellino E, Fiorini I, Ioan P, Chiarini A, Cagnotto A, Mennini T, Fracasso C, Caccia S, Campiani G.
    J Med Chem; 2009 Nov 12; 52(21):6946-50. PubMed ID: 19831400
    [Abstract] [Full Text] [Related]

  • 6. Novel selective and partial agonists of 5-HT3 receptors. Part 1. Synthesis and biological evaluation of piperazinopyrrolothienopyrazines.
    Rault S, Lancelot JC, Prunier H, Robba M, Renard P, Delagrange P, Pfeiffer B, Caignard DH, Guardiola-Lemaitre B, Hamon M.
    J Med Chem; 1996 May 10; 39(10):2068-80. PubMed ID: 8642566
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological properties of quinoxaline derivatives as a new class of 5-HT3 receptor antagonists.
    Lasheras B, Berjón A, Montañés R, Roca J, Romero G, Ramírez MJ, Del Río J.
    Arzneimittelforschung; 1996 Apr 10; 46(4):401-6. PubMed ID: 8740088
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B, Bonnaud B, Funes P, Jubault N, Koek W, Assié MB, Cosi C, Kleven M.
    J Med Chem; 1999 May 06; 42(9):1648-60. PubMed ID: 10229633
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A, Alonso-Cires L, López-Tudanca PL, Tapia I, Labeaga L, Mosquera R.
    Drug Des Discov; 2000 May 06; 16(4):271-9. PubMed ID: 10807033
    [Abstract] [Full Text] [Related]

  • 14. SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo.
    Bachy A, Héaulme M, Giudice A, Michaud JC, Lefevre IA, Souilhac J, Manara L, Emerit MB, Gozlan H, Hamon M.
    Eur J Pharmacol; 1993 Jun 24; 237(2-3):299-309. PubMed ID: 7689975
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V, Novellino E, Stark JA, Cagnotto A, Fumagalli E, Carnovali F, Cervo L, Mennini T.
    J Med Chem; 2003 Aug 28; 46(18):3822-39. PubMed ID: 12930145
    [Abstract] [Full Text] [Related]

  • 16. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
    Delgado M, Caicoya AG, Greciano V, Benhamú B, López-Rodríguez ML, Fernández-Alfonso MS, Pozo MA, Manzanares J, Fuentes JA.
    Eur J Pharmacol; 2005 Mar 21; 511(1):9-19. PubMed ID: 15777774
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
    Heightman TD, Gaster LM, Pardoe SL, Pilleux JP, Hadley MS, Middlemiss DN, Price GW, Roberts C, Scott CM, Watson JM, Gordon LJ, Holland VA, Powles J, Riley GJ, Stean TO, Trail BK, Upton N, Austin NE, Ayrton AD, Coleman T, Cutler L.
    Bioorg Med Chem Lett; 2005 Oct 01; 15(19):4370-4. PubMed ID: 16039851
    [Abstract] [Full Text] [Related]

  • 20. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
    Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR.
    J Pharmacol Exp Ther; 2001 Oct 01; 299(1):268-76. PubMed ID: 11561089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.